Results 41 to 50 of about 805 (190)

An insight into the use of estetrol-drospirenone as effective oral contraceptive

Health Sciences Review, 2023
Rise in population level is a major issue in today's world and according to United nations reports suggest the world population of 6 billion is expected to reach 9.7 billion by 2050.
Himanshu Chaudhry, Naresh K Rangra, Pooja A Chawla   +2 more
doaj   +1 more source

HPLC method for simultaneous estimation of Drospirenone & Estetrol in Tablet Dosage Form

, 2023
<p><strong><span><span>Abstract </span></span></strong></p> <p><span>An efficient and accurate method was devised to simultaneously determine the levels of Drospirenone and Estetrol in Tablet ...
Dhruvika Singh Chouhan, Anju Goyal
core   +1 more source

Estetrol Prevents Hot Flushes and Improves Quality of Life in Patients with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy: The PCombi Study

European Urology Open Science, 2022
Background: Androgen deprivation therapy (ADT) for prostate cancer (PCa) is accompanied by side effects affecting health-related quality of life (HRQL). Objective: To assess the effects of the fetal estrogen estetrol (E4) on symptoms related to estrogen ...
Yvette Zimmerman, Mark Frydenberg, Hendrik van Poppel, R. Jeroen A. van Moorselaar, Erik P.M. Roos, Diederik M. Somford, Ton A. Roeleveld, Tjard D. de Haan, Harm H.E. van Melick, Yacov Reisman, Jan Krijgh, Frans M.J. Debruyne, Herjan J.T. Coelingh Bennink   +12 more
doaj   +1 more source

Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)

European Urology Open Science, 2021
Background: Androgen deprivation therapy (ADT) for prostate cancer with luteinizing hormone-releasing hormone (LHRH) agonists can be improved. Objective: To assess safety, the frequency and severity of hot flushes (HFs), bone health, and antitumor ...
Herjan J.T. Coelingh Bennink, Jeroen A. van Moorselaar, E. David Crawford, Erik P.M. Roos, Diederik M. Somford, Ton A. Roeleveld, Tjard D. de Haan, Harm H.E. van Melick, Yacov Reisman, Yvette Zimmerman, Gonnie van Osta, Jan Krijgh, Neal D. Shore, Fred Saad, Andrew V. Schally, Frans M.J. Debruyne   +15 more
doaj   +1 more source

Estetrol: a new word in modern hormonal contraception. A review [PDF]

Гинекология
The concept of the demographic policy of the Russian Federation is to increase the birth rate, preserve citizens' health, and increase life expectancy. One of the priority areas is the reproductive health of women.
Vera N. Prilepskaya, Mariia V. Iurova
doaj   +1 more source

Sexual health of women using combined oral contraceptive containing estetrol and drospirenone: A prospective observational study

Гинекология
Aim. To evaluate the effect of a combined oral contraceptive (COC) containing estetrol and drospirenone on the sexual function of women using it. Materials and methods.
Mekan R. Orazov, Viktor E. Radzinskiy, Marina B. Khamoshina, Roman E. Orekhov, Vasily V. Ermakov   +4 more
doaj   +1 more source

Update of the EuroGuiDerm evidence‐based guideline for the treatment of acne—Short version

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 7, Page 1162-1172, July 2026.
The 2025 EuroGuiDerm guideline update provides evidence‐based recommendations for acne management, addressing systemic antibiotics, systemic isotretinoin, hormonal therapies including spironolactone and contraceptives, and new topical agents. Key considerations include treatment duration, safety, pregnancy‐specific guidance and minimizing antibiotic ...
Alexander Nast, Bassel H. Al Wattar, Marie Beylot Barry, Holger Brüggemann, Zrinka Bukvić Mokos, Dawn M. Caruana, Klaus Degitz, Clio Dessinioti, Brigitte Dréno, Rieke J. B. Driessen, Harald Gollnick, Merete Hædersdal, Alexander Katoulis, Severin Läuchli, Julien Lambert, Alison M. Layton, Giuseppe Micali, Falk R. Ochsendorf, Thozhukat Sathyapalan, Katarina Zak Stangeland, Simon Francis Thomsen, Daniel Töröcsik, Antonia Pennitz   +22 more
wiley   +1 more source

P071 - ESTETROL/DROSPIRENONE SAFETY IN A CARDIOVASCULAR RISK POPULATION [PDF]

Objectives We aimed to evaluate cardiovascular safety outcomes in a population of estetrol 15 mg/drospirenone 3 mg users with cardiovascular risk factors.
Douxfils, J; id_orcid, Foidart, JM, Danielsson, K Gemzell, Kubba, A, Creinin, MD, Gaspard, U   +5 more
core   +1 more source

Safety and evidence base of a combined oral contraceptive based on estherol and drospirenone: a brief summary

Клинический разбор в общей медицине
Family planning is a fundamental concept for building and development of society in the 21st century. The beliefs that developed over the last century and the priorities that changed resulted in the ecological and reproductive dissonance, the main ...
Mekan R. Orazov, Viktor E. Radzinsky, Evgeny D. Dolgov   +2 more
doaj   +1 more source

Estetrol/drospirenon

Pharma Selecta, 2022
De meeste orale hormonale anticonceptiva bevatten het synthetische oestrogeen ethinylestradiol. Drovelis® is een anticonceptiepil met een nieuw oestrogeen, estetrol, gecombineerd met het progestageen drospirenon. Estetrol is een oestrogeen dat van nature aanwezig is in het menselijk lichaam tijdens de zwangerschap.
Heersche, Annemarie, Truong-Nguyen , T.
openaire   +2 more sources